Susan Haigney is lead editor of BioPharm International®.
In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss the new chapter, Chapter <86> Bacterial Endotoxins Test Using Recombinant Reagents
Jason Bock, co-founder and CEO of CTMC, discusses the industry impact and manufacture of patient-centered medicines.
The agency will review the company’s supplemental new drug application for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy.
Operating in an aging facility and/or utilizing outdated equipment may lead to drug shortages and high operating costs.
With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
Chancellor of the Exchequer, Rachel Reeves, has announced a £520 million (US$675 million) investment for manufacturing capacity in the United Kingdom, prompting academic and industry leaders to point out that funds should be used to train personnel.
The expanded offices in Griesheim, Germany, feature a demonstration and training area.
The company is investing $76 million to increase ADC manufacturing capacity at its St. Louis, Mo. facility.
Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments.
In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses how facilities used for solid dosage manufacturing may be retrofitted into sustainable cell and gene therapy production facilities.
BioPharm International spoke with Kenneth LaRiviere, head of Engineering at Andelyn Biosciences, about the possible problems that can arise when operating an older facility for biopharmaceutical manufacturing.
Pfizer’s bivalent RSV prefusion F vaccine has been approved by FDA to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at increased risk.
The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.
The agency’s CHMP recommended drugs to treatments for hemophilia, two biosimilars for psoriasis, and two flu vaccines at their October meeting.
The draft joint network strategy for the EU until 2028 will be open for public consultation until Nov. 30, 2024.
This year's CPHI award winners emphasize achievements in pharma excellence.
The agency is working with the European medicines regulatory network to improve the assessment and approval process for new medications.
Contract organizations offer assistance for testing raw materials obtained from outside suppliers.
In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses factors to be considered in constructing a new facility for cell and gene therapy production as well as using an existing facility to expand cell and gene therapy pipelines.
FDA’s Darby Kozak provided commentary on the anniversary of the Drug Price Competition and Patent Term Restoration Act of 1984.
The two companies are partnering to provide logistics and manufacturing services to biotechnology and pharma companies.
Approvals were recommended for treatments of ovarian cancer, lung cancer, bleeding disorders, respiratory disease, and more.
Emerging therapies, such as cell and gene therapies, come with unique challenges that must be planned for in advance.
The agency is recommending the extension of the smallpox and mpox vaccine, Imvanex, to adolescents aged 12 to 17.
Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.
BioPharm International Editorial Advisory Board
BioPharm International spoke with our Editorial Advisory Board member, Hanns-Christian Mahler, CEO of ten23 health, about his work in the bio/pharma industry and what he sees for the industry’s future.
During a presentation at the PDA/FDA Joint Regulatory Conference, Nicholas Violand of Johnson & Johnson and Paul Palmer of Paul R. Palmer Limited discussed how aging facilities can impact the quality of pharmaceutical products.
CDER’s Jonathan Chapman, senior policy advisor, and Takeda’s Paulien Groll, head of Compliance Excellence, discussed how companies can be proactive with their CAPA strategies instead of reactive, at the 2024 PDA/FDA Joint Regulatory Conference.
In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss submitting biologics license applications and working with suppliers.
